OSTEOPORE LIMITED (OSX)

Latest AI Signal: BUY
Status: NEW
Days Old: 0

Confidence: 45%

Date: 21-05-2026

Price: $0.007

Last Price: $0.007

Latest  OSTEOPORE LIMITED(OSX)   News

14 Nov 2025, 04:47 AM

Kelyniam Global Secures Exclusive U.S. License for Evonik's VESTAKEEP® Fusion Biomaterial in Cranial Implants

Kelyniam Global Inc. CANTON, Conn., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Kelyniam Global, Inc. (OTC: KLYG), a leader in custom cranial and craniofacial implants, today announced it has secured an exclusive U.S. license from Evonik Industries AG to market VESTAKEEP® Fusion, a bi-calcium phosphate-infus

Chart available once enough post-signal price data is available.

BUY Confidence Low

AI Confidence - 45 % model confidence

Business Overview

Osteopore Limited is a medical technology company specializing in the development and commercialization of bioresorbable scaffolds and implants primarily used in craniofacial, orthopedic, and dental applications. The company operates in the niche regenerative biomaterials market, leveraging proprietary technology to address bone regeneration and repair, positioning itself as an innovative player in a growing healthcare segment.

Financial Analysis

Cash Flow	Weak
Debt	Unknown
Profitability	Weak
Revenue Trend	Unknown

Technical Analysis

Trend	Bullish
Momentum	Moderate
RSI Signal	Neutral
Support Level	$ 0.0060
Resistance Level	$ 0.0085

Valuation

Valuation - Undervalued

The stock trades at a very low price with potential upside given its innovative product pipeline and market niche, though financial metrics remain limited.

Catalysts

• Successful commercialization and adoption of new bioresorbable implant products.

• Positive clinical trial results or regulatory approvals.

• Strategic partnerships or licensing agreements expanding market reach.

Recommendation

Action - Buy

Timeframe - Medium Term

Osteopore presents a speculative buy opportunity driven by its innovative medical technology and potential market growth. Investors should weigh the early-stage financial profile against upcoming product and regulatory catalysts.